Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

Genna M. Luciani, Lihua Xie, David Dilworth, Anne Tierens, Yoni Moskovitz, Alex Murison, Magdalena M. Szewczyk, Amanda Mitchell, Mathieu Lupien, Liran Shlush, John E. Dick, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy, Mark D. Minden*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease. (C) 2018 Published by Elsevier Inc. on behalf of ISEH - Society for Hematology and Stem Cells.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalExperimental Hematology
Volume69
DOIs
Publication statusPublished - Jan 2019

Funding

The authors thank Alma Seitova (Structural Genomics Consortium) and Dan Mamelak Custom Biologics (CB) for help with cytokines. This work was supported by the Leukemia Lymphoma Society of Canada. The Structural Genomics Consortium is a registered charity (1097737) that receives funds from AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD grant no. 115766); Janssen; Merck & Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; São Paulo Research Foundation-FAPESP; Takeda; and the Wellcome Trust.

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression'. Together they form a unique fingerprint.

Cite this